| Gene Symbol | CHMP2B |
| Full Name | Charged Multivesicular Body Protein 2B |
| Chromosome | 3p11.2 |
| Protein Family | ESCRT-III complex family |
| Protein Type | Other |
| Target Class | Other |
| Function | Under physiological conditions, CHMP2B performs essential functions in the nervous system. |
| Mechanism of Action | Therapeutic agents targeting CHMP2B would modulate ESCRT-III complex function to enhance endosomal sorting and autophagy, potentially clearing protein aggregates associated with frontotemporal dementia or compensating for loss-of-function mutations. Strategies include antisense oligonucleotides to modulate protein expression, autophagy enhancers to promote cellular clearance pathways, or small molecules that stabilize ESCRT-III complex assembly and function. |
| Primary Expression | Endosomes and endolysosomal membranes |
| Druggability | Low (0.32) |
| Clinical Stage | Phase II |
| Molecular Weight | ~24 kDa |
| Amino Acids | 213 aa |
| Pathways | Lysosomal function / degradation |
| UniProt ID | Q9UQN3 |
| NCBI Gene ID | 25978 |
| Ensembl ID | ENSG00000083937 |
| OMIM | 609512 |
| GeneCards | CHMP2B |
| Human Protein Atlas | CHMP2B |
| Associated Diseases | Als, Alzheimer's disease, Amyotrophic Lateral Sclerosis, Dementia, FRONTOTEMPORAL DEMENTIA, FTD3 |
| Known Drugs/Compounds | rapamycin |
| Interactions | CHMP2A, OVERVIEW, VALOSIN, TARDBP, LC3, TBK1 |
| SciDEX Target | View Target Profile (2 clinical trials) |
| SciDEX Hypotheses | Lysosomal Membrane Repair Enhancement |
| KG Connections | 461 knowledge graph edges |
| Databases | GeneCardsHPASTRING |